Turning ultrasound into medicine: Low-intensity ultrasound unlocks precision cancer treatment
Peer-Reviewed Publication
Updates every hour. Last Updated: 1-Jul-2025 17:10 ET (1-Jul-2025 21:10 GMT/UTC)
Scientists from Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, have developed a novel ultrasound-driven therapy that activates dormant cancer drugs directly inside tumors. By combining low-intensity ultrasound with specially designed nanoparticles, the team achieved a 99% tumor suppression rate and 66.7% cure rate in mice. This non-invasive approach minimizes side effects and could revolutionize targeted cancer treatment.
• These findings emphasize the need to integrate age, pre-neoadjuvant CEA and NLR levels, PD-1 expression, and CT-detected mediastinal lymph node changes into postoperative management strategies.
• Clinical practices should adapt to routinely evaluate these parameters to better stratify patients’ risks and personalize postoperative care plans.
New urine-based tumor DNA (utDNA) test may help predict the recurrence of bladder cancer in high-risk patients and more personalized cancer treatments.
Researchers at ETH Zurich have developed a human model of lactating breast tissue using 3D printing and breast milk cells.
The cells in the tissue model produced components of human milk.
The model is designed to help better understand the processes involved in lactation.
Esophageal adenocarcinoma (EAC) is the sixth most deadly cancer worldwide for which no effective targeted therapy exists. Patients need to rely on chemotherapy which is started ahead of surgical interventions in the hope to shrink or control tumors. However, most patients become resistant to certain NACTs, leading to poor outcomes.
To enable clinicians to rapidly test different chemotherapies and determine the best treatment courses, Wyss Institute researchers and their collaborators at McGill University have developed a precision oncology Organ Chip platform that accurately and actionably predicts chemotherapy responses of individual patients with EAC in a clinically useful timeframe.